Laboratory and clinical studies on ritipenem acoxil

Y. Sawae, K. Okada, Nobuyuki Shimono, H. Misumi, K. Eguchi, Y. Niho, K. Takaki

Research output: Contribution to journalArticle

Abstract

We performed laboratory and clinical studies on ritipenem acoxil (RIPM- AC), a new oral penem antibiotic, with the following results. 1. Antimicrobial activity. Minimal inhibitory concentrations (MIC) of ritipenem (RIPM) were measured for 223 clinical isolates of 11 species, and its antimicrobial activity was compared with ampicillin (ABPC), cefaclor (CCL), cephalexin (CEX) and cefpodoxime (CPDX). The MIC values of RIPM against gram positive cocci were equal to those of ABPC, and superior to those of CCL, CEX and CPDX. In contrast, those of RIPM against gram-negative bacteria were superior to those of ABPC, CCL and CEX, but inferior to those of CPDX. 2. Clinical efficacy. The clinical efficacy of RIPM-AC was evaluated in 12 patients : 6 with pneumonia, 1 with bronchopneumonia, 3 with bronchitis, 1 with bronchiectasis and 1 with lung abscess. The patients were given a daily dose of 450~600 mg for 7~28 days. The clinical response was excellent in 2 cases, good in 8, fair in 1, and poor in 1, the efficacy rate being 83.3%. Bacterial strains were eradicated in 1 case, decreased in 4 and unchanged in 1 by treatment with RIPM-AC. As adverse reactions, dyspepsia and eosinophilia and elevation of GPT were observed in one case each.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume43
Issue numberSUPPL. 3
Publication statusPublished - Jan 1 1995

Fingerprint

cefpodoxime
Cefaclor
Cephalexin
meropenem
Lung Abscess
Bronchopneumonia
Gram-Positive Cocci
Bronchiectasis
Bronchitis
Dyspepsia
Eosinophilia
Ampicillin
Gram-Negative Bacteria
ritipenem
Clinical Studies
Pneumonia
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sawae, Y., Okada, K., Shimono, N., Misumi, H., Eguchi, K., Niho, Y., & Takaki, K. (1995). Laboratory and clinical studies on ritipenem acoxil. Japanese Journal of Chemotherapy, 43(SUPPL. 3), 165-170.

Laboratory and clinical studies on ritipenem acoxil. / Sawae, Y.; Okada, K.; Shimono, Nobuyuki; Misumi, H.; Eguchi, K.; Niho, Y.; Takaki, K.

In: Japanese Journal of Chemotherapy, Vol. 43, No. SUPPL. 3, 01.01.1995, p. 165-170.

Research output: Contribution to journalArticle

Sawae, Y, Okada, K, Shimono, N, Misumi, H, Eguchi, K, Niho, Y & Takaki, K 1995, 'Laboratory and clinical studies on ritipenem acoxil', Japanese Journal of Chemotherapy, vol. 43, no. SUPPL. 3, pp. 165-170.
Sawae Y, Okada K, Shimono N, Misumi H, Eguchi K, Niho Y et al. Laboratory and clinical studies on ritipenem acoxil. Japanese Journal of Chemotherapy. 1995 Jan 1;43(SUPPL. 3):165-170.
Sawae, Y. ; Okada, K. ; Shimono, Nobuyuki ; Misumi, H. ; Eguchi, K. ; Niho, Y. ; Takaki, K. / Laboratory and clinical studies on ritipenem acoxil. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43, No. SUPPL. 3. pp. 165-170.
@article{c846c2907137468cb046b4342c83d993,
title = "Laboratory and clinical studies on ritipenem acoxil",
abstract = "We performed laboratory and clinical studies on ritipenem acoxil (RIPM- AC), a new oral penem antibiotic, with the following results. 1. Antimicrobial activity. Minimal inhibitory concentrations (MIC) of ritipenem (RIPM) were measured for 223 clinical isolates of 11 species, and its antimicrobial activity was compared with ampicillin (ABPC), cefaclor (CCL), cephalexin (CEX) and cefpodoxime (CPDX). The MIC values of RIPM against gram positive cocci were equal to those of ABPC, and superior to those of CCL, CEX and CPDX. In contrast, those of RIPM against gram-negative bacteria were superior to those of ABPC, CCL and CEX, but inferior to those of CPDX. 2. Clinical efficacy. The clinical efficacy of RIPM-AC was evaluated in 12 patients : 6 with pneumonia, 1 with bronchopneumonia, 3 with bronchitis, 1 with bronchiectasis and 1 with lung abscess. The patients were given a daily dose of 450~600 mg for 7~28 days. The clinical response was excellent in 2 cases, good in 8, fair in 1, and poor in 1, the efficacy rate being 83.3{\%}. Bacterial strains were eradicated in 1 case, decreased in 4 and unchanged in 1 by treatment with RIPM-AC. As adverse reactions, dyspepsia and eosinophilia and elevation of GPT were observed in one case each.",
author = "Y. Sawae and K. Okada and Nobuyuki Shimono and H. Misumi and K. Eguchi and Y. Niho and K. Takaki",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "43",
pages = "165--170",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Laboratory and clinical studies on ritipenem acoxil

AU - Sawae, Y.

AU - Okada, K.

AU - Shimono, Nobuyuki

AU - Misumi, H.

AU - Eguchi, K.

AU - Niho, Y.

AU - Takaki, K.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We performed laboratory and clinical studies on ritipenem acoxil (RIPM- AC), a new oral penem antibiotic, with the following results. 1. Antimicrobial activity. Minimal inhibitory concentrations (MIC) of ritipenem (RIPM) were measured for 223 clinical isolates of 11 species, and its antimicrobial activity was compared with ampicillin (ABPC), cefaclor (CCL), cephalexin (CEX) and cefpodoxime (CPDX). The MIC values of RIPM against gram positive cocci were equal to those of ABPC, and superior to those of CCL, CEX and CPDX. In contrast, those of RIPM against gram-negative bacteria were superior to those of ABPC, CCL and CEX, but inferior to those of CPDX. 2. Clinical efficacy. The clinical efficacy of RIPM-AC was evaluated in 12 patients : 6 with pneumonia, 1 with bronchopneumonia, 3 with bronchitis, 1 with bronchiectasis and 1 with lung abscess. The patients were given a daily dose of 450~600 mg for 7~28 days. The clinical response was excellent in 2 cases, good in 8, fair in 1, and poor in 1, the efficacy rate being 83.3%. Bacterial strains were eradicated in 1 case, decreased in 4 and unchanged in 1 by treatment with RIPM-AC. As adverse reactions, dyspepsia and eosinophilia and elevation of GPT were observed in one case each.

AB - We performed laboratory and clinical studies on ritipenem acoxil (RIPM- AC), a new oral penem antibiotic, with the following results. 1. Antimicrobial activity. Minimal inhibitory concentrations (MIC) of ritipenem (RIPM) were measured for 223 clinical isolates of 11 species, and its antimicrobial activity was compared with ampicillin (ABPC), cefaclor (CCL), cephalexin (CEX) and cefpodoxime (CPDX). The MIC values of RIPM against gram positive cocci were equal to those of ABPC, and superior to those of CCL, CEX and CPDX. In contrast, those of RIPM against gram-negative bacteria were superior to those of ABPC, CCL and CEX, but inferior to those of CPDX. 2. Clinical efficacy. The clinical efficacy of RIPM-AC was evaluated in 12 patients : 6 with pneumonia, 1 with bronchopneumonia, 3 with bronchitis, 1 with bronchiectasis and 1 with lung abscess. The patients were given a daily dose of 450~600 mg for 7~28 days. The clinical response was excellent in 2 cases, good in 8, fair in 1, and poor in 1, the efficacy rate being 83.3%. Bacterial strains were eradicated in 1 case, decreased in 4 and unchanged in 1 by treatment with RIPM-AC. As adverse reactions, dyspepsia and eosinophilia and elevation of GPT were observed in one case each.

UR - http://www.scopus.com/inward/record.url?scp=0028791826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028791826&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028791826

VL - 43

SP - 165

EP - 170

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 3

ER -